ReviewCurrent cardiology reports2026
GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes.
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond Glycemic Control: Real-World 12-Month Effects of Insulin Glargine/Lixisenatide on Weight, Endogenous Insulin Secretion, and Albuminuria.Journal of clinical medicine · 2026Article
- Cardiovascular-Kidney-Metabolic (CKM) Syndrome Staging and Relevance to Precision Nutrition.Nutrients · 2026Review
- Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewWhether body mass index (BMI) influences cardiovascular and kidney outcomes of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes (T2DM) and to understand how metabolic phenotype may influence treatment response. RECENT
findingsAcross randomized trials, GLP-1 RAs consistently reduced cardiovascular events in diverse populations, with no statistically significant heterogeneity by BMI. Observational analyses suggest that individuals with overweight or obesity may experience greater absolute cardiovascular risk reduction, potentially reflecting improvements in visceral adiposity, inflammation, and insulin resistance. In contrast, renal benefits such as slower decline in kidney function, reduced albuminuria, and delayed kidney failure were uniform across BMI categories. This BMI-independent nephroprotection aligns with mechanisms involving natriuresis, reduced oxidative and inflammatory injury, and attenuation of fibrotic pathways. GLP-1 RAs provide clinically meaningful cardiovascular and kidney protection across the BMI spectrum. Cardiovascular benefits may be accentuated in individuals with elevated BMI, whereas renal benefits remain consistent regardless of adiposity. These findings support broad use of GLP-1 RAs for cardiorenal risk reduction and highlight the potential value of incorporating body-composition metrics beyond BMI in future treatment algorithms.
Indexed as
Identifiers
41880122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.